These numbers are not adjusted for the patient cap increase (last week PR) from 100 to 275, as well. None of them are.
This is PRECISELY why the LPCN is so valuable. The safety issue is directly related to the gel. There is no safe pill alternative, available, to date.
This will be a 90-120 day NDA resubmittal with proper algorithmic titration labeling. Meeting with FDA, is tentative, in the next 29 days to solidify timeline. No safety or efficacy concerns means, virtually, zero probability of necessary additional testing data.
Not going to do your work your you. The quickest I have seen was just shy of 30 days and several that were around 90 days. Average is 6 months - 1yr. 2 years if a study needs to be redone. With, LPCN, since it was a labeling issue related to the algorithmic titration a second NDA submission will occur within 1 year. There will be a meeting with the FDA to review and schedule the NDA in the next 29 days.
Yoenis, what happened to your bat? The mets offense is terrible. Noah, is your elbow alright, why is your velocity and control so poor this year?
Correct, current market capitalization is $386m 48.55m shares outstanding. With no money, previously and one product, year-aways, just starting a PII, mathematically, the floor is $2.05pps with years to bleed down.
So, cash is not decreasing but is $400m now instead of $500m...but that was only a one time thing that happened twice (so far). LMAO.
you really do not understand this, go look at MNKD. Cult retail stocks get shorted into bankruptcy. There is no plan to turn it around, the plan is to crush it into non existence.
Or...it could be because Gopro had a 147% inventory glut as reported Q3 2015 that resulted in 2 subsequent $100 price cuts to the Hero4 session model during the Xmas season (Gopro's primary earnings seasons) that has decimated product margin (all channel checks have confirmed this scenario). GoPro is streaming full throttle towards an ugly Q4 report in early February.
You, intentionally, have altered the data. I'm sure WSJ and Barron's would be thrilled to know that.
PER WSJ and Barron 12/28/15 float 50.3m. 13.8m shares short is 27.435% of 50.3m.
Center, I would be careful altering information and claiming a source. If they see this post you will get a cease and desist sent to the address sourced on the IP.
Your short percentage is wrong, it is 27.45% not 29.23% Your dividend statement is wrong, as well, as this is a bio-development company.
prcgoraman2; Diabetes association to lung dysfunction is well-documented. The AMA, John Hopkins, Harvard, ADA. Basically, I can source any major medical source currently on the planet. If you are a serious investor you should have been well aware of this reality.
Yes, Al Mann spent over $1b investing in Afrezza but, even he, acknowledges that respiratory delivery might need to be abandoned if not tangible.